A phase I study of the safety and pharmacokinetics of DNIB0600 A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC) - Gordon, M S; Gerber, D E; Infante, J R; Xu, J; Shames, D S; Choi, Y; Kahn, R S; Lin, K; Wood, K; Maslyar, D J; Burris, H A (J Clin Oncol, 2013)